Peter Clark to Predictive Value of Tests
This is a "connection" page, showing publications Peter Clark has written about Predictive Value of Tests.
Connection Strength
0.218
-
David SN, Arnold Egloff SA, Goyal R, Clark PE, Phillips S, Gellert LL, Hameed O, Giannico GA. MAGI2 is an independent predictor of biochemical recurrence in prostate cancer. Prostate. 2018 06; 78(8):616-622.
Score: 0.034
-
Pal SK, Agarwal N, Boorjian SA, Hahn NM, Siefker-Radtke AO, Clark PE, Plimack ER. National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. J Clin Oncol. 2016 09 20; 34(27):3346-8.
Score: 0.030
-
Goldstein J, Borowsky AD, Goyal R, Roland JT, Arnold SA, Gellert LL, Clark PE, Hameed O, Giannico GA. MAGI-2 in prostate cancer: an immunohistochemical study. Hum Pathol. 2016 06; 52:83-91.
Score: 0.029
-
Ritch CR, You C, May AT, Herrell SD, Clark PE, Penson DF, Chang SS, Cookson MS, Smith JA, Barocas DA. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. Urology. 2014 Jun; 83(6):1309-15.
Score: 0.026
-
Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, Shariat SF, Xylinas E, Schmitz-Dräger BJ, Lotan Y, Jenkins LC, Droller M, van Rhijn BW, Karakiewicz PI. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol. 2013 Jan; 63(1):4-15.
Score: 0.023
-
Davies JD, Aghazadeh MA, Phillips S, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, Penson DF, Smith JA, Barocas DA. Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol. 2011 Dec; 186(6):2221-7.
Score: 0.022
-
Thompson IM, Salem S, Chang SS, Clark PE, Davis R, Herrell SD, Kordan Y, Baumgartner R, Phillips S, Smith JA, Cookson MS, Barocas DA. Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methods. World J Urol. 2011 Feb; 29(1):15-20.
Score: 0.020
-
Rossi PJ, Urbanic J, Clark PE, McCullough DL, Lee WR. Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone. Brachytherapy. 2008 Oct-Dec; 7(4):286-9.
Score: 0.018
-
Papagikos MA, Rossi PJ, Urbanic JJ, deGuzman AF, McCullough DL, Clark PE, Lee WR. A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone. Am J Clin Oncol. 2007 Apr; 30(2):199-204.
Score: 0.016